Post-ERCP pancreatitis: Randomized, prospective study comparing a low- and high-osmolality contrast agent

Stuart Sherman, Robert H. Hawes, Scott W. Rathgaber, Michael F. Uzer, Milton T. Smith, Qazi E. Khusro, William B. Silverman, Dee Ann T. Earle, Glen A. Lehman

Research output: Contribution to journalArticle

82 Scopus citations

Abstract

Diagnostic and therapeutic ERCPs are complicated by pancreatitis in 1% to 10% of patients, and evidence suggests that the contrast agent used for ERCP may be important in the pathogenesis of such pancreatitis. This prospective, double-blind study was undertaken to determine whether the use of a low- osmolality, nonionic contrast agent (Omnipaque 300; iohexol, 672 mOsm/kg H2O) would reduce the frequency and severity of postprocedure pancreatitis as compared to a high-osmolality, ionic contrast agent (Hypaque 50%; diatrizoate sodium, 1515 mOsm/kg H2O). Six hundred ninety patients undergoing diagnostic ERCP (pancreatogram, cholangiogram, or both) either with or without sphincter of Oddi manometry and therapy were randomized to iohexol or diatrizoate sodium. Postprocedure pancreatitis was diagnosed when the serum amylase or lipase level was elevated to at least four times the upper limits of normal at 18 hours and was associated with increased abdominal pain persisting for at least 24 hours after the procedure that required administration of narcotic analgesics. The pancreatitis was graded as mild, moderate, or severe depending on the length of hospital stay and the need for intervention. The overall frequency (7.2% versus 7.5%) and severity (4.3% mild, 2% moderate, 0.9% severe for the diatrizoate sodium group versus 4.3% mild, 2.6% moderate, and 0.6% severe for the iohexol group) of postprocedure pancreatitis and the frequency and severity within each procedure category were similar for the two contrast agent groups (p > .05). Similarly, no statistical difference was noted (p > .05) in the incidence and severity of postprocedure pancreatitis for the two contrast agent groups when the data were analyzed for patients who had had a pancreatogram (8.8% versus 9%). In conclusion, the incidence and severity of postprocedure pancreatitis is not altered by the use of iohexol. In view of the relatively high cost of this agent, its routine use for ERCP is not recommended.

Original languageEnglish (US)
Pages (from-to)422-427
Number of pages6
JournalGastrointestinal endoscopy
Volume40
Issue number4
DOIs
StatePublished - Jan 1 1994

    Fingerprint

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

Sherman, S., Hawes, R. H., Rathgaber, S. W., Uzer, M. F., Smith, M. T., Khusro, Q. E., Silverman, W. B., Earle, D. A. T., & Lehman, G. A. (1994). Post-ERCP pancreatitis: Randomized, prospective study comparing a low- and high-osmolality contrast agent. Gastrointestinal endoscopy, 40(4), 422-427. https://doi.org/10.1016/S0016-5107(94)70204-7